AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17932841 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day application of topical 0.5% levofloxacin
Number of subjects: 100
Study 17932841 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (after levofloxacin applications)
Number of subjects: 100
Study 15474628 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom resolution by day 14
Number of subjects: 399
Study 15474628 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom scores at presentation
Number of subjects: 399
Study 15474628 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom scores comparison
Number of subjects: 399
Study 15474628 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to return to work
Number of subjects: 399
Study 11175234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal transtracheal augmented ventilation (TTAV) at 10 L/min
Number of subjects: 15
Study 11367663 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingyu Jiuxin Pills (QYJXP)
Number of subjects: 58
Study 11367663 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISD)
Number of subjects: 58
Study 8154033 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin (500 mg)
Number of subjects: 28
Study 8154033 — intervention group
Group type: COMPARATOR
Intervention: placebo (100 ml)
Number of subjects: 28
Study 29316960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 150-300 mg twice daily for 8 weeks
Number of subjects: 38
Study 29316960 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (GBP) 400-800 mg three times daily for 8 weeks
Number of subjects: 38
Study 27488235 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise 5 d/wk for 16 wk combined with modest calorie restriction (∼0.84 MJ/d)
Number of subjects: 79
Study 27488235 — intervention group
Group type: EXPERIMENTAL
Intervention: Global analysis of gene expression
Number of subjects: 79
Study 24615491 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive virtual poverty simulation in Second Life, 2.5 hours, delivered three times over 1 year
Number of subjects: 51
Study 24615491 — intervention group
Group type: COMPARATOR
Intervention: Self-study module
Number of subjects: 51
Study 22883608 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose 5-ALA (15 mg capsule)
Number of subjects: 154
Study 22883608 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose 5-ALA (50 mg capsule)
Number of subjects: 154
Study 22883608 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo capsule)
Number of subjects: 154
Study 19890660 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine posture during cycling
Number of subjects: 11
Study 19890660 — intervention group
Group type: COMPARATOR
Intervention: Upright posture during cycling
Number of subjects: 11
Study 19486056 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid soap containing 12% ammonium lactate + 20% urea
Number of subjects: 36
Study 19486056 — intervention group
Group type: COMPARATOR
Intervention: Placebo liquid soap
Number of subjects: 36
Study 16449478 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 361
Study 16449478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 15459595 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (15 mg/kg IV over 24 hours followed by 200 mg orally 3 times per day for 7 days)
Number of subjects: 160
Study 15459595 — intervention group
Group type: COMPARATOR
Intervention: Sotalol (80 mg orally 2 times per day for 7 days)
Number of subjects: 160
Study 15459595 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (in patients undergoing AVR or CABG with AVR)
Number of subjects: 160
Study 15459595 — intervention group
Group type: COMPARATOR
Intervention: Sotalol (in patients undergoing AVR or CABG with AVR)
Number of subjects: 160
Study 15459595 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 160
Study 11174041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid, vitamin B6, and vitamin B12 supplements
Number of subjects: 0
Study 11174041 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of folic acid, vitamin B6, and vitamin B12 supplements
Number of subjects: 0
Study 11174041 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical/surgical management
Number of subjects: 0
Study 9253332 — intervention group
Group type: COMPARATOR
Intervention: PTHrP (parathyroid hormone-related peptide-(1-34))
Number of subjects: 8
Study 8494580 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (0.14 mg/nostril b.i.d.)
Number of subjects: 193
Study 8494580 — intervention group
Group type: COMPARATOR
Intervention: Budesonide nasal aerosol (0.05 mg/nostril b.i.d.)
Number of subjects: 193
Study 8494580 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 193
Study 8494580 — intervention group
Group type: COMPARATOR
Intervention: Budesonide nasal aerosol
Number of subjects: 193
Study 8494580 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray and Budesonide nasal aerosol
Number of subjects: 193
Study 3320788 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol, a new beta-adrenergic blocking agent with direct vasodilator activity, administered orally.
Number of subjects: 0
Study 3320788 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 31753737 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone with patient navigation (IM + PN)
Number of subjects: 225
Study 31753737 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone (IM)
Number of subjects: 225
Study 31753737 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (ETAU)
Number of subjects: 225
Study 31753737 — intervention group
Group type: COMPARATOR
Intervention: Combined IM groups (IM + PN and IM)
Number of subjects: 225
Study 31753737 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (IM + PN, IM, ETAU)
Number of subjects: 225
Study 30085876 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel deproteinization, acid etching, bonding agent application, and pit & fissure sealant placement
Number of subjects: 206
Study 30085876 — intervention group
Group type: COMPARATOR
Intervention: Acid etching followed by pit & fissure sealant application only
Number of subjects: 206
Study 27714541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily during a 12-week lead-in stage)
Number of subjects: 45
Study 27714541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (after randomization)
Number of subjects: 45
Study 27714541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (during lead-in stage)
Number of subjects: 45
Study 27714541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after randomization)
Number of subjects: 45
Study 24990101 — intervention group
Group type: EXPERIMENTAL
Intervention: Full portion aerated drink (1,000 ml, 190 kcal)
Number of subjects: 47
Study 24990101 — intervention group
Group type: EXPERIMENTAL
Intervention: Half portion aerated drink (500 ml, 95 kcal)
Number of subjects: 47
Study 24990101 — intervention group
Group type: COMPARATOR
Intervention: Full portion liquid drink (325 ml, 190 kcal)
Number of subjects: 47
Study 24990101 — intervention group
Group type: COMPARATOR
Intervention: Half portion liquid drink (162 ml, 95 kcal)
Number of subjects: 47
Study 24990101 — intervention group
Group type: EXPERIMENTAL
Intervention: Water saturated with N2 O
Number of subjects: 47
Study 24990101 — intervention group
Group type: COMPARATOR
Intervention: Water saturated with CO2
Number of subjects: 47
Study 22515902 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 30
Study 22515902 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Plus
Number of subjects: 30
Study 22515902 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 30
Study 22515902 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine and MTA Plus
Number of subjects: 30
Study 20684675 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (32-33°C)
Number of subjects: 34
Study 20684675 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia
Number of subjects: 34
Study 20684675 — intervention group
Group type: COMPARATOR
Intervention: Control group (diagnostic lumbar puncture to rule out infection)
Number of subjects: 34
Study 20684675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hypothermia and normothermia groups
Number of subjects: 34
Study 18201301 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injections into the submandibular and parotid glands; 25 units of BoNT‐A into each gland.
Number of subjects: 48
Study 18201301 — intervention group
Group type: COMPARATOR
Intervention: Control group received no treatment.
Number of subjects: 48
Study 15989411 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg daily
Number of subjects: 50
Study 15989411 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg daily
Number of subjects: 50
Study 15989411 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg + CEE 0.625 mg daily
Number of subjects: 50
Study 15989411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12558724 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive instrument based on functional status at admission, cognitive function, and social support.
Number of subjects: 781
Study 12558724 — intervention group
Group type: EXPERIMENTAL
Intervention: PHD scores of 0 or 1
Number of subjects: 781
Study 10494116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 15 mg trospium chloride in 40 ml saline
Number of subjects: 6
Study 10494116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 30 mg trospium chloride in 40 ml saline
Number of subjects: 6
Study 10494116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of trospium chloride (both dosages)
Number of subjects: 6
Study 8702086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (conjugated estrogens, 0.625 mg/d and medroxyprogesterone, 5 mg/d)
Number of subjects: 42
Study 8702086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 17
Study 1751030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6751514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery followed by cis-platinum containing combination chemotherapy
Number of subjects: 39
Study 6751514 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 39
Study 30060292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision
Number of subjects: 91
Study 30060292 — intervention group
Group type: COMPARATOR
Intervention: Vertical skin incision
Number of subjects: 91
Study 29017511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical wrist traction (12 treatments, twice a week for 6 weeks)
Number of subjects: 181
Study 29017511 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 181
Study 29017511 — intervention group
Group type: COMPARATOR
Intervention: Mechanical wrist traction and Care as usual
Number of subjects: 181
Study 25943680 — intervention group
Group type: EXPERIMENTAL
Intervention: H + H (32 ± 1 °C, 50% RH, 16.6% O2 normobaric hypoxia)
Number of subjects: 18
Study 25943680 — intervention group
Group type: EXPERIMENTAL
Intervention: H + H
Number of subjects: 18
Study 25943680 — intervention group
Group type: EXPERIMENTAL
Intervention: RPEWU
Number of subjects: 18
Study 24368400 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day plus erlotinib 150 mg/day
Number of subjects: 133
Study 24368400 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg/day
Number of subjects: 133
Study 22553307 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with mitral surgery
Number of subjects: 1212
Study 22553307 — intervention group
Group type: COMPARATOR
Intervention: CABG without mitral surgery
Number of subjects: 1212
Study 22553307 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1212
Study 22553307 — intervention group
Group type: COMPARATOR
Intervention: CABG with mitral surgery versus CABG alone
Number of subjects: 1212
Study 20014909 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg/day)
Number of subjects: 10
Study 20014909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17585060 — intervention group
Group type: EXPERIMENTAL
Intervention: A2/A2 genotype (n = 872)
Number of subjects: 1611
Study 17585060 — intervention group
Group type: COMPARATOR
Intervention: A1/A1 or A1/A2 genotype (n = 486)
Number of subjects: 1611
Study 14739125 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 10 mg daily
Number of subjects: 40
Study 14739125 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 30 mg daily
Number of subjects: 40
Study 14739125 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 60 mg daily
Number of subjects: 40
Study 14739125 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 120 mg daily
Number of subjects: 40
Study 14739125 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 120 mg twice daily
Number of subjects: 40
Study 14739125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11408427 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute heavy resistance exercise (AHRE)
Number of subjects: 10
Study 11408427 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 9403145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamblers (N = 15)
Number of subjects: 15
Study 9403145 — intervention group
Group type: COMPARATOR
Intervention: Spouses (N = 15)
Number of subjects: 15
Study 9403145 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 15)
Number of subjects: 15
Study 8094169 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex scanning
Number of subjects: 52
Study 8094169 — intervention group
Group type: COMPARATOR
Intervention: Descending phlebography
Number of subjects: 52
Study 8094169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending phlebography
Number of subjects: 52
Study 3113329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil (75 children), given once daily
Number of subjects: 150
Study 3113329 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin (75 children), given three times daily
Number of subjects: 150
Study 31975475 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical selenium (Se)
Number of subjects: 0
Study 31975475 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 0
Study 31975475 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic selenium (Se)
Number of subjects: 0
Study 30760296 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural nudge intervention with improved positioning and attractive labelling of fruit and vegetables in school cafeterias over a three-week period.
Number of subjects: 176
Study 30760296 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention).
Number of subjects: 176
Study 28363480 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/day TRF-budesonide
Number of subjects: 150
Study 28363480 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/day TRF-budesonide
Number of subjects: 150
Study 28363480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 25692789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting diathermy
Number of subjects: 66
Study 25692789 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 66
Study 24191330 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of flurbiprofen (tablet Flurso)
Number of subjects: 22
Study 24191330 — intervention group
Group type: COMPARATOR
Intervention: Branded product of flurbiprofen (tablet Ansaid)
Number of subjects: 22
Study 21193552 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine
Number of subjects: 60
Study 21193552 — intervention group
Group type: COMPARATOR
Intervention: SC ketamine
Number of subjects: 60
Study 19825056 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Number of subjects: 25
Study 19825056 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 25
Study 19126934 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 0
Study 19126934 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 0
Study 14747426 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH administered in a fasting state
Number of subjects: 0
Study 14747426 — intervention group
Group type: COMPARATOR
Intervention: d‐MPH administered after a high‐fat breakfast
Number of subjects: 0
Study 14747426 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH administered with food
Number of subjects: 0
Study 12745746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% glycine infusion at 0.5 ml/kg/min for 30 min
Number of subjects: 12
Study 12745746 — intervention group
Group type: COMPARATOR
Intervention: 3% mannitol infusion (control)
Number of subjects: 12
Study 12745746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% glycine infusion
Number of subjects: 12
Study 9825681 — intervention group
Group type: EXPERIMENTAL
Intervention: Single surgeon continuity schedule
Number of subjects: 214
Study 9825681 — intervention group
Group type: COMPARATOR
Intervention: Staff of surgeons continuity schedule
Number of subjects: 214
Study 9825681 — intervention group
Group type: EXPERIMENTAL
Intervention: Both schedules
Number of subjects: 214
Study 8085509 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Treatment Team (HTT)
Number of subjects: 54
Study 8085509 — intervention group
Group type: COMPARATOR
Intervention: Conventional community services (Control)
Number of subjects: 54
Study 2502795 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 12
Study 2502795 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 12
Study 2502795 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 4 mg
Number of subjects: 12
Study 2502795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1099489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (Orudis)
Number of subjects: 14
Study 1099489 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 14
Study 30346099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg
Number of subjects: 35
Study 30346099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 35
Study 30346099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg
Number of subjects: 35
Study 30346099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 28321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-procedural myocardial deformation imaging in the cardiac catheter laboratory (CLab)
Number of subjects: 123
Study 28321497 — intervention group
Group type: COMPARATOR
Intervention: Two-step determination of myocardial viability by cardiovascular magnetic resonance (CMR)
Number of subjects: 123
Study 25451704 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1390
Study 25451704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1390
Study 23881910 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (7 days administration)
Number of subjects: 10
Study 23881910 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alcohol)
Number of subjects: 10
Study 21420908 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 5927
Study 21420908 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD (Selective Oropharyngeal Decontamination)
Number of subjects: 5927
Study 21420908 — intervention group
Group type: EXPERIMENTAL
Intervention: SDD (Selective Digestive Tract Decontamination)
Number of subjects: 5927
Study 21420908 — intervention group
Group type: EXPERIMENTAL
Intervention: SDD
Number of subjects: 5927
Study 21420908 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD
Number of subjects: 5927
Study 19673941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day for 12 weeks
Number of subjects: 365
Study 19673941 — intervention group
Group type: COMPARATOR
Intervention: Control group (246 subjects without CHD)
Number of subjects: 365
Study 17909199 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Erlotinib
Number of subjects: 120
Study 17909199 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Chemotherapy
Number of subjects: 120
Study 17909199 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 120
Study 17909199 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 120
Study 15529490 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of the deciduous canine only
Number of subjects: 46
Study 15529490 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of the deciduous canine with cervical pull headgear
Number of subjects: 46
Study 15529490 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 46
Study 11189801 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% price reduction
Number of subjects: 0
Study 11189801 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% price reduction
Number of subjects: 0
Study 11189801 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% price reduction
Number of subjects: 0
Study 11189801 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotional signage (low-fat label plus promotional sign)
Number of subjects: 0
Study 11189801 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotional signage (low-fat label)
Number of subjects: 0
Study 11189801 — intervention group
Group type: COMPARATOR
Intervention: No promotional signage
Number of subjects: 0
Study 11189801 — intervention group
Group type: COMPARATOR
Intervention: Equal price
Number of subjects: 0